Trial Profile
An Open-label Extension Study of the Double-blind, Randomized, Parallel Group, Multicenter Phase 2 Study 307000A to Further Evaluate the Safety and Tolerability of Betaseron® 500 mcg Subcutaneously Every Other Day and Betaseron® 250 mcg Subcutaneously Every Other Day in Patients With Relapsing-remitting Multiple Sclerosis (RRMS).
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Interferon beta-1b (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions
- Acronyms BEYOND
- Sponsors Bayer HealthCare Pharmaceuticals
- 07 Jul 2009 Actual patient number changed from 60 to 63 as reported by ClinicalTrials.gov.
- 16 Sep 2008 BEYOND identified as acronym by ClinicalTrials.gov.
- 16 Sep 2008 Actual end date (Jan 2008) added as reported by ClinicalTrials.gov.